TITLE

COMMENTARY: Review: Bisphosphonates prevent or delay skeletal events in women with advance breast cancer and bone metastases

AUTHOR(S)
O'Regan, Ruth
PUB. DATE
March 2006
SOURCE
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p39
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents a study which reveals that Bisphosphonates prevent or delay skeletal events in women with advance breast cancer and bone metastases. Bisphosphonates have a wide spectrum of uses in breast cancer. Researchers reviewed the use of bisphosphonates in 3 specific breast cancer related situations. The researchers noted that the use of bisphosphonates in patients with bone metastases definitely reduces the rate of skeletal-related events (SREs). Zoledronate, the most potent bisphosphonate currently available, is at least as effective as pamidronate in preventing SREs and has a much-reduced infusion time.
ACCESSION #
20297599

 

Related Articles

  • Denosumab reduced skeletal events in women with breast cancer and bone metastases.  // Hem/Onc Today;11/25/2008, Vol. 9 Issue 21, p54 

    The article discusses research being done on the effect of denosumab on skeletal-related events in women with breast cancer and bone metastases who had not received intravenous (IV) bisphosphonate. It references a study by Allan Lipton et al, which appeared in the 2008 issue of "Clinical Cancer...

  • Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Clemons, M.; Gelmon, K. A.; Pritchard, K. I.; Paterson, A. H. G. // Current Oncology;Oct2012, Vol. 19 Issue 5, p259 

    Most women with advanced breast cancer will develop bone metastases, which are associated with the development of skeletal-related events (sres) such as pathologic fractures and spinal cord compression. This article reviews the evolving definition and incidence of sres, the pathophysiology of...

  • Review: Bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastases.  // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p39 

    This article reports that Bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastases. 15 randomized controlled trials (RCTs) in women with advanced breast cancer and clinically evident bone metastases, 3 RCTs in women with advanced breast cancer...

  • ENDURING METASTATIC CANCER PAIN. Arathuzik, Mary // Oncology Nursing Forum;Mar2006, Vol. 33 Issue 2, p459 

    Oncology nurses often care for cancer patients who are experiencing pain particularly patients with metastatic disease. Understanding key factors encountered by metastatic cancer patients who are enduring pain should provide nurses with valuable insights into how cancer patients deal with pain....

  • Bone metastases: Zometa to become the gold-standard treatment?  // PharmaWatch: Cancer;May 2003, Vol. 2 Issue 5, p22 

    Examines the use of bisphosphonates in bone metastasis of breast and prostate cancer. Use of Aredia and Zometa drugs to treat bone metastasis; Rate of occurrence of bone metastasis in patients with breast and prostate cancer; Role of Novartis in marketing the drugs.

  • Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Oster, Gerry; Lamerato, Lois; Glass, Andrew G.; Richert-Boe, Kathryn E.; Lopez, Andrea; Chung, Karen; Richhariya, Akshara; Dodge, Tracy; Wolff, Greg G.; Balakumaran, Arun; Edelsberg, John // Supportive Care in Cancer;Dec2013, Vol. 21 Issue 12, p3279 

    Purpose: To document the risk of skeletal complications in patients with bone metastases from breast cancer (BC), lung cancer (LC), or prostate cancer (PC) in routine clinical practice. Methods: We used data from two large US health systems to identify patients aged ≥18 years with...

  • Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. Ning Jia; Cormack, Fionnuala C.; Bin Xie; Zita Shiue; Najafian, Behzad; Gralow, Julie R. // BMC Cancer;Jul2015, Vol. 15 Issue 1, p1 

    Background: Renal toxicity has been reported with bisphosphonates such as pamidronate and zolidronate but not with ibandronate, in the treatment of breast cancer patients with bone metastasis. One of the patterns of bisphosphonate-induced nephrotoxicity is focal segmental glomerulosclerosis...

  • Assessment of treatment response in lobular breast carcinoma metastatic to skeleton. Ghesani, Munir; Dy, Irene; Cohen, Seth; Rosenbaum-Smith, Sharon; DeLara, Francisco; Kodsi, Karen; Moran, Christopher // Hem/Onc Today;6/10/2012, Vol. 13 Issue 11, p14 

    The article discusses the case of a 55-year-old hypertensive female patient with breast cancer who is diagnosed with bone metastases after she underwent mastectomy.

  • Research on bone metastases quickens its pace. Ziegler, Jan // JNCI: Journal of the National Cancer Institute;06/18/97, Vol. 89 Issue 12, p841 

    Focuses on the affinity of bone metastasis on breast cancer patients. Recognition of bone metastasis as a hazard in many cancers; Development of classes of drugs applicable to bone diseases; Mechanisms of tumor cells production; Use of nude mice in observing the osteolytic metastases in humans;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics